| Theme | PSC and PBC -- Recent Progress in Diagnosis and Treatment | |
|---|---|---|
| Title | Medical Treatment of Primary Sclerosing Cholangitis | |
| Publish Date | 2014/10 | |
| Author | Ryuichi Yamamoto | Department of Gastroenterology, Hiroshima Memorial Hospital / Department of General Internal Medicine, Hirosima University of Medical Science |
| Author | Keishi Kanno | Department of General Internal Medicine, Hirosima University of Medical Science |
| Author | Shuichi Iwamoto | Department of General Internal Medicine, Hirosima University of Medical Science |
| Author | Susumu Tazuma | Department of General Internal Medicine, Hirosima University of Medical Science |
| [ Summary ] | There are no established drug treatments for PSC. Patients with end stage PSC require liver transplantation. Recent reports concerning RCT have revealed that UDCA, which is frequently used for PSC, is unlikely to improve long-term outcomes. In addition, high-dose UDCA has been reported to increase the risk of colorectal neoplasia in patients with ulcerative colitis concomitant with PSC. In Japan, bezafibrate is the second most widely used agent to treat UDCA, although no certain evidence of its efficacy exists. Recent information concerning PSC medication is summarized. | |